Disease relevance of Nasonex

• Alternate day application of mometasone 0.1% for 2 weeks was as effective as once-daily application in maintaining symptom control in a small number of patients with psoriasis vulgaris [1].
• In patients with seborrhoeic dermatitis, mometasone 0.1% was more effective than ketoconazole 2.0% and hydrocortisone 1.0% in trials lasting 4 or 6 weeks [1].
• Transient, mild to moderate, local adverse effects such as burning, stinging, folliculitis, dryness, acneiform eruptions and signs of skin atrophy have been reported with mometasone [1].
• Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease [2].
• The results indicated that mometasone is effective in allergic rhinitis, not only during the period of application, but also after the interruption of application [3].

Psychiatry related information on Nasonex

• Results: Mometasone significantly (P < 0.05) attenuated response time profiles vs. placebo for peak nasal inspiratory flow but not total nasal symptom scores [4].
• Better patient compliance could be expected with the convenience of mometasone cream being applied daily [5].

High impact information on Nasonex

• After stratification into tertiles by baseline eosinophil count, the net improvement in post-bronchodilator FEV(1) increased with mometasone compared with placebo progressively from the least to the most eosinophilic tertile [2].
• CONCLUSIONS: An increased sputum eosinophil count is related to an improvement in post-bronchodilator FEV(1) following treatment with inhaled mometasone in COPD, but the improvement is not associated with a reduction in the sputum eosinophil count [2].
• Mometasone is a well tolerated topical glucocorticoid effective in the management of patients with atopic dermatitis, seborrhoeic dermatitis, scalp psoriasis and psoriasis vulgaris [1].
• In addition to its low potential for causing primary sensitisation and cross-reactions with other topical glucocorticoids, mometasone offers the convenience of once-daily administration [1].
• There are no documented epidemiological studies with intranasal corticosteroids (e.g. budesonide, fluticasone propionate, mometasone) during pregnancy; however, inhaled corticosteroids (e.g. beclomethasone) have not been incriminated as teratogens and are commonly used by pregnant women who have asthma [6].

Biological context of Nasonex

• The passive cutaneous anaphylaxis titer in the mometasone-treated group was significantly lower than that in the control group [3].
• Aims To compare the pharmacokinetic profiles of beclometasone, budesonide, fluticasone and mometasone following inhalation in patients with asthma, and explore the relationship between lung function and plasma drug concentrations [7].
• Methods Thirty subjects with asthma and a forced expiratory volume in 1 s (FEV(1)) ranging from 36 to 138% predicted, inhaled 800 microg beclometasone, budesonide and mometasone and 1000 microg fluticasone in random order [7].
• In contrast, mometasone inhibited human neutrophil apoptosis in a concentration-dependent manner [8].

Anatomical context of Nasonex

• In the presence of added cytokines, mometasone further enhanced neutrophil survival induced by the granulocyte-macrophage colony-stimulating factor and leukotriene B(4) [8].

Associations of Nasonex with other chemical compounds

• Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis [9].
• INTERVENTION: All patients were surgically treated in the ENT Department, University of Siena Medical School. One month after surgery, group 1 patients (n = 97) started treatment with intranasal furosemide, group 2 (n = 40) received no therapeutic treatment, and group 3 (n = 33) were treated with mometasone [10].
• RESULTS: RU24858 (1 muM) increased CXCR4 and Annexin 1 expression on eosinophils to a similar extent as mometasone (1 muM) and dexamethasone (1 muM) [11].

Gene context of Nasonex

• In addition, functionally RU24858 seems to be a less potent glucocorticoid as it did not reverse IL-5- and GM-CSF-afforded eosinophil survival similarly to dexamethasone and mometasone [11].
• Like dexamethasone and mometasone, RU24858 did suppress IL-8 and MCP-1 production in eosinophils [11].
• OBJECTIVE: To compare the effects of budesonide and mometasone on nasal symptoms and nasal airflow in perennial allergic rhinitis [12].
• The present data suggests that mometasone has opposite effects on apoptosis of human eosinophils and neutrophils at clinically relevant drug concentrations via an effect on glucocorticoid receptor [8].

Analytical, diagnostic and therapeutic context of Nasonex

• Mometasone has shown a low risk of primary sensitisation and cross-reactions in preliminary patch test studies [1].
• A comparison of nasal clearance after treatment of perennial allergic rhinitis with budesonide and mometasone [13].

References